Synoptics Technologies provides IT infrastructure and networking solutions, including cloud migration, data center design, and managed services for government and enterprise clients.
The company lacks a durable moat as evidenced by declining margins and a significant drop in profitability despite stable revenues. The business operates in a highly competitive IT services segment with low switching costs, corroborated by a negative cash conversion cycle and poor pricing power.
Capital allocation is concerning; while the company raised significant funds via an IPO, it has struggled to generate positive operating cash flow. Reinvestment in capital work-in-progress and intangible assets has not yet translated into earnings growth, with EPS declining over the period.
The investment collapsed because the reported profits never turned into actual cash, as evidenced by the negative cash conversion cycle and massive unbilled revenue. The SEBI investigation into IPO fund misappropriation likely led to a total loss of institutional trust and a permanent impairment of the company's ability to raise capital or win new contracts. As trade receivables aged and unbilled revenue was eventually written off, the thin margins evaporated, leaving a hollowed-out shell of a business that could no longer service its liabilities or compete in a commoditized IT market.
RichFakir rates Synoptics Technologies Ltd's business quality as poor — 36/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Synoptics Technologies Ltd is trading about 20% below our estimate of fair value; we rate its price fair. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Synoptics Technologies Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Synoptics Technologies Ltd's fair value is about ₹64 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →